Thelansis

 Synovial sarcoma, a malignant soft tissue tumor, presents as a high-grade malignancy with a poor prognosis despite its peculiar lack of origin from the synovium. Typically manifesting in monophasic or biphasic forms, it most commonly emerges around the knee region. Among soft tissue sarcomas, it holds the highest propensity for bone metastasis, particularly afflicting adolescents and children, with a peak incidence observed in the third decade of life (median age, 36 years) and a higher prevalence among females. Approximately ninety percent of synovial sarcoma cases exhibit a translocation of t(x;18)(p11;q11), resulting in a fusion between the SYT and SSX genes, leading to derepression and increased transcription. Unlike its counterparts, synovial sarcoma often manifests with pain. Cytogenetic analysis for the t(x;18)(p11;q11) translocation has emerged as a reliable diagnostic tool for synovial sarcoma. Imaging studies prove invaluable in determining tumor invasion into adjacent b...

  Synovial Sarcoma (SS) is a soft tissue sarcoma that mimics a benign neoplasm due to its slow growth and distal predisposition. A slow-growing mass, compression symptoms, or irritation to nearby structures are all common symptoms of SS. These cancers are well-known for their proclivity for being misdiagnosed. They've been said to look like arthritis, synovitis, bursitis, hemangiomas, and hematomas, especially when small calcifications accompany them. SS affects specific areas, with 60 percent to 70 percent of cases affecting the lower extremity, and is frequently associated with bursae, tendon sheaths, and joint capsules. Monophasic and biphasic SS are the two major subtypes of SS histologically. Monophasic tumors, found in all three of our patients, are made up of spindled cells and have a better prognosis. They usually present as smaller masses with no metastases. The incidence of Synovial Sarcoma (SS) varies from 3.2 to 4.65 cases per million populations in the USA. ...